For the quarter ending 2025-09-30, GANX had $2,113,056 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,284,373 | -10,339,145 |
| Depreciation and amortization | 22,817 | 42,988 |
| Stock-based compensation expense | 460,005 | 941,523 |
| Other non-cash items | -10,864 | -782,880 |
| Prepaid expenses and other current assets | -866,395 | 1,252,940 |
| Long term deposit and other noncurrent assets | -541 | -1,778 |
| Accounts payable and other current liabilities | -949,139 | 1,265,791 |
| Defined benefit pension plan | -35,307 | -68,395 |
| Deferred grant income | -18,239 | -294,989 |
| Total changes in operating assets and liabilities | 135,749 | 348,755 |
| Cash used in operating activities | -4,926,436 | -8,920,509 |
| Net proceeds from issuance of shares in atm offering (note 14) | 0 | 4,910,240 |
| Net proceeds from issuance of shares and warrants in public offering (note 14) | 7,411,554 | - |
| Net proceeds from the exercise of warrants (note 14) | 41,745 | - |
| Payments of offering costs (note 14) | 395,478 | - |
| Payments of current portion of long-term debt (note 12) | 24,996 | 46,480 |
| Cash provided by financing activities | 7,032,825 | 4,863,760 |
| Effect of exchange rate changes | 6,667 | 369,605 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 2,113,056 | -3,687,144 |
| Cash and cash equivalents at beginning of period | 10,417,558 | - |
| Cash and cash equivalents at end of period | 8,843,470 | - |
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)